NCT02226146 - Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions

Pemphigoid, Bullous

Interventions

BIOLOGICAL

Bertilimumab

Trial Locations (8)

University of Cleveland, Cleveland

Sourasky-Ichilov Tel Aviv Medical Center, Tel Aviv

Chaim Sheba MC, Tel-Hashomer, Ramat Gan

University of Iowa, Iowa City

University at Buffalo, Buffalo

Icahn School of Medicine at Mount Sinai, New York

Duke University Medical Center, Durham

University of Utah, Salt Lake City